Skip to main content
. Author manuscript; available in PMC: 2022 Oct 24.
Published in final edited form as: Chem Biol Drug Des. 2020 Mar 13;95(6):584–599. doi: 10.1111/cbdd.13671

Figure 7: Compound VS14 promotes FAK delocalization and prevents cellular adhesion.

Figure 7:

(A) Immunofluorescent-staining of FAK in HER2+ MDA-MB-453 breast cancer cells treated with DMSO or 10 μM compound VS14. In DMSO treated cells, FAK was localized to focal adhesions (white asterisks). In VS14 treated cells, FAK was de-localized from focal adhesions and clustered in the cytoplasm. HER2 and Paxillin localization was unchanged by VS14 treatment, supporting the FAK specificity of VS14. (B) In MDA-MB-453 breast cancer cells, VS14 pre-treated cells did not attach to fibronectin-coated coverslips, unlike DMSO treated cells. The VS14 treated cells were round and lacked focal adhesions.